Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04B UROLOGICALS
G04BD Drugs for urinary frequency and incontinence
G04BD12 Mirabegron
D09535 Mirabegron (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Genitourinary Agents
Antispasmodics, Urinary
Beta-3 Adrenergic Agonists
Mirabegron
D09535 Mirabegron (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
25 Urogenital and anal organ agents
259 Miscellaneous
2590 Miscellaneous
D09535 Mirabegron (JAN/USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01455 beta-Adrenergic receptor agonist
DG01453 beta3-Adrenergic receptor agonist
D09535 Mirabegron
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D09535 Mirabegron
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
D09535 Mirabegron
Transporter inhibitor
DG01622 ABCB1 inhibitor
D09535 Mirabegron
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRB3
D09535 Mirabegron (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09535
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09535
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09535
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09535
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09535
Drug transporters
D09535